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Accepted 25 November 2014Cesarean scar pregnancy (CSP) is a rare form of ectopic preg-
nancy where implantation of the gestational sac occurs at the
previous scar with the surrounding myometrium [1]. The incidence
reported by Seow et al [2] was extremely low (approximately 1 in
2000), which is consistent with the prevalence of 1:1800 reported
by Jurkovic et al [3].
The precise mechanism is still not clear and poorly understood.
Implantation of the conceptus into the myometrium through a
microscopic tract or scar defect had been suggested [4]. Cata-
strophic and life-threatening complications such as uterine rupture
and massive hemorrhage could occur in case of misdiagnosis.
Therefore, prompt and early diagnosis is essential to facilitate early
intervention.
This is a case of CSP successfully treated with local injection of
methotrexate (MTX) and hypertonic dextrose solution. Subsequent
vaginal bleeding after the termination of CSP was effectively
controlled by tranexamic acid followed by gonadotropin releasing
hormone analog (GnRHa). This approach resulted in avoidance of
surgical intervention.
A 30-year-old gravida 3 para 2 woman in the 9th week of
amenorrhea who had two previous cesarean sections (CSs), was
referred for an incidental ﬁnding of CSP during her ﬁrst antenatal
visit. She was asymptomatic, and the result of her physical ex-
amination was unremarkable. An ultrasound scan noted a gesta-
tional sac embedded at the previous CS scar. The pregnancy was
considered viable with a crown rump length of 25.8 mm. The
uterine cavity was empty with no free ﬂuid seen in the pouch of
Douglas (Figs. 1e3). Her serum beta human chorionic globulin* Corresponding author: Department of Obstetrics and Gynaecology, Universiti
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patient was asymptomatic and hemodynamically stable, she was
treated medically. A direct injection of MTX into the gestational
sac was performed under transvaginal scan guidance. A repeat
ultrasound scan 3 days later showed persistent fetal heart activity;
however, she remained asymptomatic. Therefore, another intra-
gestational sac injection was given using 10 mL hypertonic
dextrose 50%, which successfully led to the cessation of fetal heart
activity 3 days later. She had persistent vaginal spotting with no
abdominal pain. Serial beta-hCG showed a decreasing trend to a
level of < 1.2 mIU/mL 4 months later although the gestational sac
remained visible.
Soon after the beta-hCG level had normalized, the amount of
vaginal bleeding increased. She sought medical help from a private
gynecologist, who gave her an intramuscular depo medrox-
yprogesterone acetate (150 mg). However, the vaginal bleeding
worsened to the point where she required blood transfusion. She
was readmitted to our center for further management. Fortunately,
despite heavy vaginal bleeding, there was no abdominal pain and
she remained hemodynamically stable. The couple was counseled
for laparoscopic resection of the gestational sac but they were very
reluctant. The sac was noted to be round and remained at the same
size (3.4 cm  2.8 cm). Therefore, intravenous tranexamic acid was
administered, which effectively reduced the vaginal bleeding fol-
lowed bya trial of GnRHa (Lucrin PDS depot 3.75mg; Abbvie, Zuellig
Pharma, Takeda, Japan). She was successfully managed with a dose
of three monthly injections of GnRHa after which she became
amenorrheic. The couple was advised on the potential risk of scar
rupture in future pregnancy. She was given combined oral contra-
ceptive pills, and she has remained well with regular menstrual
cycles. The ectopic gestational sac was completely absorbed 1 year
after the therapy.
With the increasing rate of CSs worldwide, the rate of CSP was
likewise expected to increase although it is rare. The incidence of
CSP was < 0.05% [2]. For women with ectopic pregnancy with at
least one previous CS, its rate was 6.1% [2]. Conﬂicting results were
reported with regard to the association between risks of CSP and
number of previous CSs. Multiple CS was thought to be associated
with an increased risk of CSP [3]. However, Rotas et al [5] could not
demonstrate its correlation with the number of CSs (52% after 1 CS,
36% after 2 CSs, and 12% after  3 CSs).by Elsevier Taiwan LLC. All rights reserved.
Fig. 1. Enlarged image of fetal echo with demonstration of fetal heart activity.
Fig. 3. Transvaginal ultrasound image showing a gestational sac implanted anteriorly
into the cesarean section scar. The bladder wall is seen just adjacent to the gestational
sac.
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endogenic and exogenic. The endogenic type occurs when the
gestational sac is implanted on the cesarean scar, and may later
progress into intrauterine pregnancy, which subsequently results
to giving birth to a live fetus. The exogenic type arises from a deeply
implanted gestational sac into the defect of a scar and may later
grow toward the bladder or abdominal cavity [6]. The former type
may result in a more favorable outcome (i.e., viable fetus with the
risk of morbidly adherent placenta), but the latter would probably
progress to uterine rupture and severe hemorrhage [7,8].
The mean gestational age at diagnosis was generally about
6.9e7.5 weeks [2,5], and the average duration between CS to cur-
rent pregnancy was reported to be between 6 months and 12 years
[2]. In reported cases where presenting symptoms could be
assessed, although the majority were diagnosed early (< 9 weeks),
most cases had either vaginal bleeding or abdominal pain [9e14].
Asymptomatic cases were mainly diagnosed at  8 weeks' gesta-
tion [15e17]. Our patient was asymptomatic and she was 9 weeksFig. 2. A midline sagittal transabdominal scan image showing a gestational sac with
fetal echo seen implanted at previous cesarean scar. The uterine cavity is empty. The
myometrium anterior to the gestational sac is thinned out.pregnant when the diagnosis of CSP was made, and her last CS
occurred 1 year ago.
Ultrasound scan, especially high-frequency transvaginal so-
nography, aids in the early diagnosis of CSP, thereby allowing a
more conservative approach [2,6] with higher success rates in
medical treatment. The ultrasonographic criteria for diagnosing a
CSP include an empty uterine cavity with no gestational sac in the
cervical canal, and pregnancy located anterior to the uterine
isthmus with a defective myometrial layer was found between the
gestational sac and the urinary bladder [2,4]. The trophoblastic ﬂow
surrounding the gestational masswas reported to be prominent [9].
Various options of managementdincluding systemic or local
administration of MTX, uterine artery embolization (UAE), dilata-
tion and curettage (D&C), local resection of the gestational mass via
laparoscopy or laparotomy, as well as hysterectomydhad been
reported with different success rates.
The surgical approach with evacuation techniques alone (i.e.,
D&C) was not recommended for CSP owing to the high risk of
massive hemorrhage, except for selected cases [1]. Rotas et al [5]
performed a systematic review on CSP. They reported that only
23% of patients who were managed primarily by D&C were un-
complicated, and the remaining 76% of patients required systemic
MTX, laparotomy excision of the ectopic mass, or hysterectomy [5].
Resection of the CSP had been performed via the vaginal
approach [13], laparoscopy [14,18], or laparotomy [7] with good
outcomes. He et al [13] reported on a successful transvaginal
approach to remove CSP and repair the uterine defect in six pa-
tients. None of the patients required conversion to laparotomy [13].
This approach requires surgeons to be familiar with vaginal surgery
as it is a narrow surgical ﬁeld and difﬁculties might be encountered.
Similarly, the laparoscopic approach requires skillful laparoscopists
who are capable of suturing laparoscopically and able to handle
difﬁcult situations.
MTX had been used effectively in tubal and cervical pregnancies
particularly in gestational age < 9 weeks, fetal pole < 10 mm,
absence of fetal heart activity, and serum HCG < 10,000 mIU/mL
[19]. A local injection of MTX directly into the gestational sac of a
CSP had the advantage of minimizing side effects produced by
systemic MTX administration. It yields an excellent result either
alone [9], in combination with potassium chloride into the fetal
thorax [4], or in combinationwith UAE and potassium chloride [15].
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[11] and misoprostol [12]. Although surgical intervention might be
avoided, medical therapy carries the risk of failure and slow
regression of hCG level, and requires prolonged follow-up. This
patient was diagnosed at 9 weeks' gestation with a viable CSP and
serum hCG of > 60,000 mIU/mL. Fetal heart activity persisted after
3 days of local MTX, and her CSP was successfully terminated with
additional intragestational sac hypertonic dextrose 50%. Her HCG
level only declined to a normal range 4 months after the treatment,
whereas complete absorption of the ectopic mass took 1 year.
Persistent bleeding after medical treatment requiring further
intervention is not an uncommon problem even though hCG may
be undetectable. Additional interventions described include mul-
tiple intragestational injection, D&C, UAE, Foley balloon tampo-
nade, wedge resection, and hysterectomy [5]. There was no
consensus regarding the best approach for this issue. Pang et al [17]
described the use of tranexamic acid followed by repeated UAEs in
a patient who developed heavy vaginal bleeding 102 days after
medical treatment. UAE was performed owing to the presence of
uterine arteriovenous ﬁstula feeding a venous aneurysm. Four
doses of GnRHa were given to reduce uterine vascularity [17].
This patient had increased vaginal bleeding soon after hCG
normalized and her condition worsened after receiving intramus-
cular depo medroxyprogesterone acetate. Her bleeding was suc-
cessfully reduced by tranexamic acid. She became amenorrheic
after receiving GnRHa without requiring invasive intervention. The
use of combined oral contraceptive pills subsequently did not lead
to excessive vaginal bleeding although the ectopic mass remained
at the CS scar. There were two possible explanations for the
increment in vaginal bleeding. (1) One factor could be the
resumption of menstruation following normalization of hCG. The
presence of persistent gestational sac in the cesarean scar leads to
heavymenstruation. (2) Another explanation is the development of
arteriovenous malformation (AVM) as described by Lin et al [20]
and Kochhar et al [21]. However, we did not investigate further to
distinguish the cause of heavy vaginal bleeding.
The aim of using GnRHa in this case was to create a pseudo-
menopausal amenorrheic state while waiting for the spontaneous
absorption of the CSP mass. The reduction of uterine vascularity
following GnRHa leading to the regression of AVM had been
described by Nonaka et al [22], whereas Pang et al [17] described
the regression of post-CSP venous aneurysm by GnRHa in
conjunction with embolization. If AVM had been present in this
case, regression of AVM by GnRHa could be another reason for the
resolution of symptoms.
In conclusion, early and accurate diagnosis of CSP is achieved
with the advancement of ultrasound scan, thus enhancing the
success of medical treatment in CSP. GnRHa is a potential effective
adjuvant therapy for CSP with persistent vaginal bleeding after
medical treatment where invasive intervention might be avoided.Conﬂicts of interest
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